TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05839314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Huaier granule, oral administration, 10g each time, 3 times a day, continuous medication for 24 weeks. After 24 weeks of treatment, the dosage should be adjusted according to efficacy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin-angiotensin-aldosterone system inhibitors (RASI)
Description: Run-in period: All the patients should be treated with RASI for at least 4 weeks, and stop using any medicine containing Huaier or similar ingredients for at least 2 weeks before enrollment. If the patient is receiving RASI, the RASI can be continued until the end of the study. RASI can be adjusted once a week until the maximum tolerable dose based on albuminuria and blood pressure. If the patient is not receiving RASI therapy, then RASI is recommended.~Treatment period: RASI therapy is continued throughout the trial. Check blood pressure twice daily: morning and evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin-aldosterone system inhibitors (RASI)
Description: Run-in period: All the patients should be treated with RASI for at least 4 weeks, and stop using any medicine containing Huaier or similar ingredients for at least 2 weeks before enrollment. If the patient is receiving RASI, the RASI can be continued until the end of the study. RASI can be adjusted once a week until the maximum tolerable dose based on albuminuria and blood pressure. If the patient is not receiving RASI therapy, then RASI is recommended.~Treatment period: RASI therapy is continued throughout the trial. Check blood pressure twice daily: morning and evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin soft capsules
Description: The initial dose of Ciclosporin soft capsules is an oral dose of 3.5mg/kg/d, divided into two equal doses, given every 12 hours. Assess the plasma concentration of CsA (valley value) every 2 weeks in the first 8 weeks. If the plasma concentration of CsA reaches 100-150ug/L, continue to maintain the dose. If the plasma concentration of CsA is below the target concentration, increase the dose of CsA. If the plasma concentration of CsA is higher than the upper limit of the target concentration, appropriate dose reduction. A single dose adjustment is 25mg/d. After increasing/decreasing the dose, CsA concentration is remeasured at intervals of 2 weeks ±3 days until the target concentration is reached.~CsA at target concentration followed by 24 weeks of treatment, then the dosage shall be adjusted according to efficacy.
Study: NCT05457647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Riboflavin/UV-A corneal cross-linking
Description: Corneal cross-linking procedure will be performed using the theranostic software module of the C4V CHROMO4VIS™ system in all participants. Participants will receive a single dose of the 0.22% riboflavin ophthalmic solution, RitSight™. Application of the riboflavin eye drop will be done for 15 minutes for the EpiOFF CXL treatment and 20 minutes for the EpiON CXL treatment. Estimates of riboflavin concentration into the cornea will be monitored by the C4V CHROMO4VIS™ system during the dosing phase of treatment. Once the dosing phase is completed, the C4V CHROMO4VIS™ system provides the Operator the access to the UV-A irradiation of the cornea with 5.4 J/cm2 total energy dose and 7.00 mm light beam diameter in all participants. Estimates of treatment efficacy by calculation of theranostic score will be performed by the C4V CHROMO4VIS™ system during UV-A irradiation.
Study: NCT06497049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP40221
Description: Solution for Subcutaneous Administration 1.34 mg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ozempic
Description: Solution for Subcutaneous Administration 1.34 mg/ml
Study: NCT04854915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOOP + mHealth technology assisted exercise counselling
Description: Participants will complete a 3 month exercise and physical activity intervention supported by mHealth technology

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LOOP Only
Description: Participants will complete the LOOP @ Alder Hey programme
Study: NCT06162286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: Omadacycline IV/PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin IV/PO
Study: NCT05686512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-by-Step
Description: The Step-by-Step follows a stepped care approach, were all children (and caregivers) complete the first step (a brief group intervention followed by an individual session). Those with more needs are offered to continue to step 2 where individual CBT is given. See Figure 1 for a schematic representation of the stepped care approach, and Table 2 for an overview of session content.~Step 1 Session 1-4: Group sessions including psychoeducation, parenting skills and mapping stress and vulnerability factors, exposure and coping skills (90 minutes) Session 5: Individual session - If ending after step 1 a maintenance plan is completed. If continuing to step 2 continued exposure and selection of optional focus areas such as emotion regulation, social skills, stress- and vulnerability factors, child worry or parental worry. (45 minutes)~Step 2 Session 6-8: Individual sessions - Exposure and selected focus areas. (45 minutes)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cool Kids
Description: The Cool Kids Program is an Australian manualized group CBT treatment of child anxiety, which has been broadly implemented in Sweden. Several studies have found evidence of its efficacy.~Session 1-10: Group sessions including psychoeducation, cognitive restructuring (gather evidence to reevaluate anxiety related thoughts), parent skills, exposure, social skills, coping skills (cognitive and behavioral strategies to handle anxiety reactions, learning problem-solving skills). (120 minutes)
Study: NCT04779866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered Hypnosis
Description: Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered White Noise Hypnosis
Description: Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
Study: NCT06511921

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: early biologic therapy
Description: biologic therapy for perforated Crohn's disease in the early postoperative period
Study: NCT04887662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented vegetable
Description: Participants will be asked to consume 100 g of fermented vegetables per day, at least 5 days per week, for 8 weeks
Study: NCT06082466

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FRAMED Infrainguinal Venous Bypass
Description: The harvested vein graft will be covered with a mesh.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Autologous Bypass
Description: The harvested vein graft will be used without a mesh coating.
Study: NCT06178172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote home monitoring
Description: After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. At home, patients receive guidance for the management of pain, nutrition and pancreatitis-related complaints by a daily phone call from a nurse from the Virtual Monitoring Centre (VMC). The pancreatitis-related complaints, intake of fluids and food, pain and the use of analgesics are assessed using short questionnaires in a smartphone app. Core temperature is monitored using an ear thermometer and a wearable sensor measures heart rate, respiratory rate, posture and movement every 5 minutes. Remote home monitoring will continue for at least 4 days.
Study: NCT04517916

Intervention type: DEVICE
Intervention: Zephyr Valve
Description: Subjects prescribed Zephyr Valve treatment for their emphysema/COPD and treated with the Zephyr Valves.
Study: NCT04543032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensorimotor training
Description: Sensorimotor exercises progressed from stable surfaces to unstable surfaces, training gait in a line (tandem walk or walking straight) followed by gait including change in directions, gait without obstacles to gait with obstacles, change in the support base (feet apart and then together), physical exercises with eyes opened and closed, always respecting the functional capacity of each patient and progressively increasing the difficulty of each exercise. To help the training, cones, balance board, bars, mats and a mini-trampoline will be used. According to the patient progress, the exercises will be combined, generating circuits
Study: NCT06277011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolically Armed CD19 CAR-T cells
Description: Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
Study: NCT05949138

Intervention type: DEVICE
Intervention: ECG-Less Cardiac CT using SmartPhase
Description: Administration of medications and biologic products (such as contrast agent administration, and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational workflow on an existing CT device that has regulatory clearance. The investigational workflow includes preforming the CT acquisition according to the hospital's usual care with the exception that the ECG signal which triggers the scan will be coming from an ECG simulator based on an estimate of the patient's heart rate, rather than through ECG leads connected to the subject. Clinically-indicated Cardiac CTs take approximately 30-60 minutes. No additional imaging is needed as part of the study.
Study: NCT05924373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Dental Fulp Stem Cells
Description: Investigational drugs: Based on the initial periodontal treatment (supragingival cleansing, subgingival scaling and root planning), human pulp stem cell injections will be given for a single or two local injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Dental Fulp Stem Cells
Description: Investigational drugs: Based on the initial periodontal treatment (supragingival cleansing, subgingival scaling and root planning), human pulp stem cell injections will be given for a single or two local injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Dental Fulp Stem Cells
Description: Investigational drugs: Based on the initial periodontal treatment (supragingival cleansing, subgingival scaling and root planning), human pulp stem cell injections will be given for a single or two local injection
Study: NCT04936958

Intervention type: OTHER
Intervention: patients having had an osteomyelitis since 2017
Description: description of osteomyelitis and their management
Study: NCT05839743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The aerobic exercise program will be specially prepared for the participants and will aim to rhythmically exercise large muscle groups. The exercise will be performed twice a week for 6 weeks at 50-75% of maximum heart rate for 20-50 minutes per session. Each exercise will last 30-60 minutes in total, after adding 5 minutes of warm-up and 5 minutes of cool-down before and after the exercise. The participant's pulse will be monitored continuously during the exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Exercise
Description: Balance exercises belonging to the Otago Exercise Program and other balance exercises used in the elderly will be prepared specifically for the participant and will be applied 2 days a week for 6 weeks in combination. Before and after the exercise, a 5-minute warm-up and 5-minute cool-down exercise will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Exercise
Description: In the combined exercise program, first balance exercises and then aerobic exercise program will be applied 2 days a week for 6 weeks.
Study: NCT05057819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Treatment naive patients with bariatric bypass surgery will be given oral empagliflozin 25mg once daily for 20 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: Treatment naive patients with bariatric bypass surgery will be given oral empagliflozin 25mg once daily for 20 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Treatment naive patients with bariatric bypass surgery will be given oral placebo once daily for 20 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment naive patients with bariatric bypass surgery will be given oral placebo once daily for 20 days
Study: NCT06451705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PECS II block
Description: Treatment group that received the PECS II block using isobaric bupivacaine 0.5% 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LIA
Description: Treatment group that received the local infiltration anesthesia using isobaric bupivacaine 0.5% 50 mg
Study: NCT06281639

Intervention type: DEVICE
Intervention: RAPID
Description: test the clinical screening potential for congenital heart disorders using a single ECHO image taken by the RAPID device
Study: NCT05174013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279
Description: GSK3858279 will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered
Study: NCT02459392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Drug administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoMedrol
Description: Drug administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoMedrol
Description: Drug administration
Study: NCT04949438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.
Study: NCT05702216

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation
Description: Hybrid approach in cardiac telerehabilitation. Patients underwent 20 cardiac rehabilitation sessions: alternatively, patients underwent 10 classical cardiac rehabilitation sessions in the clinic and 10 cardiac telerehabilitation sessions at home.

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation
Description: Hybrid approach in cardiac telerehabilitation. Patients underwent 20 cardiac rehabilitation sessions: alternatively, patients underwent 10 classical cardiac rehabilitation sessions in the clinic and 10 cardiac telerehabilitation sessions at home.
Study: NCT06485271

Intervention type: DRUG
Intervention: Camrelizumab
Description: 200mg,iv,d1,Q2W/Q3W

Intervention type: DRUG
Intervention: Camrelizumab
Description: 200mg,iv,d1,Q2W/Q3W

Intervention type: DRUG
Intervention: Camrelizumab
Description: 200mg,iv,d1,Q2W/Q3W

Intervention type: DRUG
Intervention: apatinib
Description: 250mg,qd

Intervention type: DRUG
Intervention: apatinib
Description: 250mg,qd

Intervention type: DRUG
Intervention: apatinib
Description: 250mg,qd

Intervention type: DRUG
Intervention: chemotherapy
Description: Standard treatment

Intervention type: DRUG
Intervention: chemotherapy
Description: Standard treatment

Intervention type: DRUG
Intervention: chemotherapy
Description: Standard treatment
Study: NCT06075485

Intervention type: OTHER
Intervention: Ketocal
Description: ketogene diet
Study: NCT06017661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds
Description: 2 times a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutridrink Skin Repair
Description: 2 times a day
Study: NCT05981209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study: NCT06032156

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose β-OHB
Description: Ingestion of a low dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.3 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose β-OHB
Description: Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of a taste-matched calorie-free placebo drink followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
Study: NCT05784142

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: * Part 1: Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.~* Part 2: patients will be treated with hypofractionated radiation therapy in doses up to 48-60 Gy at 4 Gy per fraction.~* Part 3: patients with partial response or stable disease after part 2 will be eligible for immunotherapy maintenance, for up to 1 years or until disease progression or unacceptable toxicity.
Study: NCT06119256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-TCR-T cells
Description: The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\^5/kg to 1×10\^6/kg EBV-TCR-T cells per dose.
Study: NCT05174871

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: Lifestyle intervention (usual treatment for patients with obesity). The behavioral intervention will last for 2 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Lifestyle intervention (usual treatment for patients with obesity). The behavioral intervention will last for 2 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRF intervention
Description: Food intake restricted to 8 hours per day during the window between 10h and 22h. Time restricted feeding will take place 6 days per week, with the seventh day unrestricted. The intervention will last for 2 months.
Study: NCT04694859

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation
Description: Transfemoral or transapical Transcatheter Aortic Valve Implantation
Study: NCT06360445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Tablet test formulation 100mg
Description: A generic product manufactured by CSPC Ouyi Pharmaceutical Co., Ltd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib Tablet reference formulation 100mg
Description: Olaparib Tablet reference formulation 100mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Tablet test formulation 150mg
Description: Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Tablet test formulation 150mg
Description: Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib Tablet reference formulation 150mg
Description: Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib Tablet reference formulation 150mg
Description: Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
Study: NCT05185739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pre-operative Pembrolizumab (200mg IV every 3 weeks) for 2 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Pre-operative Lenvatinib (8 or 12mg PO once daily according to bodyweight \<60gk≥) for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and Lenvatinib
Description: Pre-operative combination of pembrolizumab and lenvatinib at the standard doses and duration as per cohort 1 and 2
Study: NCT06415695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education sessions
Description: Ten 40-minute education sessions appropriate to Saudi people will be developed and will cover essential topics for enhancing diet, lifestyle, and health. Each session comprises four modules, including activities and homework reviewed by a dietitian. Based on the EMPOWER weight loss program developed by the Nakamura lab for the US population, adjustments will be made to align with Saudi preferences, including food choices and cooking methods. Participants will access these materials online.
Study: NCT06032273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Investigator-designed lung transplant education website
Description: Caregiver participants assigned to the intervention will access the investigator-designed educational resource via their login to a secure website.